S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ENTO Entero Therapeutics Inc

0.6499

0.0279 (4.49%)

Jan 02 2025 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Entero Therapeutics (NASDAQ:ENTO)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Entero Therapeutics Charts.

Entero Therapeutics (NASDAQ:ENTO)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Entero Therapeutics Charts.

Entero Therapeutics Inc News

Form 8-K - Current report
Wednesday 27 November 2024 (1 month ago) • Edgar (US Regulatory)

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
Thursday 14 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (2 months ago) • Edgar (US Regulatory)

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
Wednesday 13 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Monday 21 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 10 October 2024 (3 months ago) • Edgar (US Regulatory)

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
Tuesday 10 September 2024 (4 months ago) • GlobeNewswire Inc.

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
Friday 23 August 2024 (4 months ago) • GlobeNewswire Inc.

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
Wednesday 31 July 2024 (5 months ago) • GlobeNewswire Inc.

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
Thursday 27 June 2024 (6 months ago) • GlobeNewswire Inc.

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
Wednesday 22 May 2024 (7 months ago) • GlobeNewswire Inc.

More Entero Therapeutics Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions